Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Dottikon Es Holding AG    DESN   CH0582581713

DOTTIKON ES HOLDING AG

(DESN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Dottikon ES : Condensed Annual Report 2018/19

05/28/2019 | 01:05am EST

2018/19 Condensed Annual Report Your Specialist for Hazardous Reactions.

3 DOTTIKON ES

Condensed Annual Report 2018/19

Content

Summary/Outlook

5

Group Financial Statements DOTTIKON ES Group

15

Consolidated Income Statements

16

Consolidated Balance Sheets

17

Consolidated Cash Flow Statements

18

Consolidated Statements of Changes in Equity

19

Notes

20

Corporate Governance

31

Investor Relations

41

The Annual Report 2018/19 in English includes only condensed financial information.

The comprehensive Annual Report 2018/19 is available in German.

5 Summary/Outlook DOTTIKON ES Group

Condensed Annual Report 2018/19

Dear Shareholder,

Herewith we present to you DOTTIKON ES Group's Condensed Annual Report 2018/19 for the period from April 1, 2018, to March 31, 2019. Despite a clearly stronger second business half- year, net sales and net income for the full business year 2018/19 remained below the previous year's figures on the back of a weak first business half-year as a result of increased sourcing complexity, campaign interruptions, and the resulting production and delivery acceptance delays.

This year's Annual Report is dedicated to our new laboratory facility G017, which was officially inaugurated on May 10, 2019. It currently offers workplaces for 150 employees in the areas of routefinding, process design, chemical process and analytical method development, quality assurance, product safety, validation, registration, and quality control, with an option to expand to 200 workplaces with little time of preparation. This allows DOTTIKON ES to satisfy the risen market demand for services related to chemical process development and the manufacturing of active pharmaceutical ingredients.

Review

At CHF 147.7 million, net sales in the business year 2018/19 were 6.6 percent lower than in the previous year. Compared with the already strong second half of the previous business year, net sales for the second business half-year 2018/19 rose by 3.3 percent to CHF 91.1 million. The production output for the full business year - net sales plus inventory changes in semi-finished

6 Summary/Outlook DOTTIKON ES Group

Condensed Annual Report 2018/19

7 Summary/Outlook DOTTIKON ES Group

Condensed Annual Report 2018/19

and finished goods - declined by 1.6 percent compared to the previous year. The strong increase in semi-finished and finished goods by CHF 12.2 million reflects the high order volume for the ongoing business year 2019/20. Despite lower net sales, together with the more material-intensive product mix, this increase in inventory resulted in a CHF 3.6 million increase in material expenses compared to the previous year. The increase in personnel expenses of 3.2 percent was roughly at par with the 3.3 percent buildup in the average full-time equivalent employees to handle the strong increase in order volumes and rise in market demand in the second business half-year. In the reporting year, existing projects and customer relationships were further developed, while new projects were acquired and new customer relations were built. Overall, this contributed significantly to the broad-based growth in the second half of the business year 2018/19. In the reporting year, lower net sales, the increase in semi-finished and finished goods, the related increase in material expenses, and higher personnel expenses resulted in an EBITDA of CHF 39.9 million, 15.3 percent lower than in the previous year, and an EBITDA

KEY FIGURES, APRIL-MARCH

CHF million

2017/18A

2018/19

Changes

A Restated, see "Changes in

Net sales

158.2

147.7

-6.6%

Corporate Accounting Principles",

pages 20 and 21

EBITDA

47.1

39.9

-15.3%

EBITDA margin (in % of net sales)

29.7%

27.0%

EBIT

30.8

20.2

-34.5%

EBIT margin (in % of net sales)

19.5%

13.6%

Net income

25.8

16.3

-37.1%

Net income margin (in % of net sales)

16.3%

11.0%

Cash flow from operating activities

39.2

38.2

-2.6%

Employees (FTE, annual average)

573

592

3.3%

margin of 27.0 percent (previous year: 29.7 percent). When looking at the second business

half-year alone, EBITDA was CHF 30.1 million (previous year: CHF 27.2 million), thus 10.8 percent above the previous-year period. The EBIDTA margin for this period was 33.0 percent (previous year: 30.8 percent). Depreciation and amortization for the full business year 2018/19 stood at CHF 19.7 million, thus 21.2 percent above the previous-year figure, mainly due to an impairment of CHF 4 million. Performed planning for a new chemical multipurpose plant in the business year 2018/19 was partially impaired due to challenging subsoil foundation properties that forced a redimensioning of the project. In the reporting year, higher depreciation and amortization resulted in an EBIT of CHF 20.2 million and a net income of CHF 16.3 million, 34.5 percent and 37.1 percent below the previous year's results, respectively. The EBIT margin stood at 13.6 percent (previous year: 19.5 percent), the net income margin at 11.0 percent (previous year: 16.3 percent). In the second business half-year and excluding the impairment, the EBIT margin was 23.9 percent (previous year: 22.0 percent) and the net income margin was 19.2 percent (previous year: 18.5 percent), which illustrates the accelerated momentum of the second business half-year.

Despite a significant increase in cash outflows from investments in additional development and production capacities by around 37 percent to CHF 48.8 million, cash and cash equivalents only decreased by CHF 10.7 million to CHF 43.8 million thanks to strong cash flow from operating activities of CHF 38.2 million (previous year: CHF 39.2 million). The equity ratio remains around 80 percent.

8 Summary/Outlook DOTTIKON ES Group

Condensed Annual Report 2018/19

9 Summary/Outlook DOTTIKON ES Group

Condensed Annual Report 2018/19

Assessment of situation

Geopolitical risks with the key players United States, Russia, and China remain present and unpredictable. This intensifies the potential for economic and fiscal, but also military conflicts. Global economic risks persist and have increased due to record global debt and a slowdown of the economic momentum. Demographic developments, the accelerated market approval for generics, biosimilars, and novel drugs, the attempt by the US government to reduce drug prices, and the steep rise in drug demand in China, combined with inexpensive capital, are key volume growth and innovation drivers in the pharmaceutical market.

The demographic developments continue to ensure further long-term volume growth. Global life expectancy continues to rise, even though it has started to lose momentum in industrialized nations where life expectancy is already at high levels. The aging population, and hence the demand for drugs, continue to rise.

Due to state-imposed efforts to boost generics and cut health care costs, the global volume share of generics for prescription and over-the-counter drugs has increased to around 90 per- cent, but given the lower prices, they only account for 40 percent of global sales. The sales share of patent-protected drugs remains at around 60 percent, and with annual growth rates of 4 to 7 percent in the coming years, it is set to outgrow the generics share, where growth is expected at 2 to 5 percent. Contrary to the tactics adopted by the rest of the world, the United States have so far tried to curb the rising health care costs by stepping up the economic competition. Pharmaceutical companies tried to combat the pressure from rebates by continually increasing their list prices. This has focused public attention on the steep increase in drug list prices and animated politicians to step up for drug price regulation. At this point, the overall impact of these measures is not clear yet.

Innovation of biopharmaceutical companies remains high. In 2018, the FDA approved a record 59 novel drugs. At roughly three-quarters, the share of small molecules was comparable to the previous year. On average, the FDA is expected to approve more than 50 novel drugs annually over the coming 5 years. Small and medium-sized biotech companies account for a significant percentage of innovation, and they increasingly introduce their products into the market by themselves. Large pharmaceutical companies are facing lower returns on their research and development expenses due to a lack of in-house innovation.

For the years ahead, expected annual growth rates for the global pharmaceutical market stand at 3 to 6 percent, slightly below the growth rates seen over the last few years. More than 50 percent of global growth is linked to the 3 main indication areas oncology, diabetes, and auto­ immune diseases. The main growth markets will be the United States and the currently second- largest pharma market China, followed by the most important European nations Germany, Italy, France, Great Britain, and Spain. In China, economic growth over the past few years and the improved health care system have given more Chinese patients access to drugs.

Due to a still promising pharmaceutical market for innovative drugs, low interest rates, and a lack of investment alternatives, financing in the biotech sector remains favorable. Many bio- techs have taken advantage of the favorable financing environment and have raised enough money to finance their main activities for a few years. A radical financial market correction, how- ever, could have a significant detrimental impact on the currently intact environment. In less favorable financing conditions, biotechs will reduce their expenses and focus their resources on the most promising product candidates.

The trend to repatriate drug substance and drug product manufacturing from Asia to the West continues, mainly driven by concerns regarding supply, quality, intellectual property, intensified

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Dottikon ES Holding AG published this content on 28 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 28 May 2019 05:03:02 UTC


© Publicnow 2019
All news about DOTTIKON ES HOLDING AG
2020DOTTIKON ES HOLDING AG : SPLIT: 10 of 1
FA
2020Dottikon ES CEO Plans to Retain Control With 72% Stake; Shares Jump 9%
MT
2020Dottikon ES Soars 16% as Shareholders OK Stock Split, Capital Raise
MT
2020DOTTIKON ES : Shareholders Approve all Proposals of the Board of Directors
PU
2020Dottikon ES to Invest $304 Million in New Chemical Multipurpose Production Pl..
MT
2020Dottikon ES Stock Drops as Fiscal H1 Net Income Soars 37%
MT
2020HALF-YEAR REPORT 2020/21 : Growth, Higher Profitability and Construction of New ..
PU
2020DOTTIKON ES HOLDING AG : half-yearly earnings release
2020DOTTIKON ES : Shareholders Approve all Proposals of the Board of Directors
PU
2020DOTTIKON ES : Condensed Annual Report 2019/20
PU
More news
Financials
Sales 2020 175 M 196 M 196 M
Net income 2020 33,2 M 37,2 M 37,2 M
Net cash 2020 42,8 M 48,0 M 48,0 M
P/E ratio 2020 24,3x
Yield 2020 -
Capitalization 2 427 M 2 728 M 2 722 M
EV / Sales 2019 3,47x
EV / Sales 2020 4,36x
Nbr of Employees 630
Free-Float 21,4%
Chart DOTTIKON ES HOLDING AG
Duration : Period :
Dottikon Es Holding AG Technical Analysis Chart | DESN | CH0582581713 | MarketScreener
Technical analysis trends DOTTIKON ES HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
NameTitle
Markus Blocher Chairman, Chief Executive Officer & MD
Marlene Born Chief Financial Officer
Urs Bršndli Head-Processes & Technologies
Alfred Scheidegger Non-Executive Director
Stephan Kirschbaum Head-Business Development
Sector and Competitors
1st jan.Capitalization (M$)
DOTTIKON ES HOLDING AG15.48%2 728
MERCK KGAA6.09%78 272
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD6.24%26 461
KYOWA KIRIN CO., LTD.0.14%14 584
BETTA PHARMACEUTICALS CO., LTD.12.74%7 529
YUHAN CORPORATION1.60%4 306